Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG…

Overview of attention for article published in Breast Cancer Research and Treatment, June 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#6 of 4,676)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 58 news outlets
policy: 2 policy sources

twitter: 1 X user

Citations

dimensions_citation: 145 Dimensions

Readers on

mendeley: 109 Mendeley

Summary News Policy documents X Dimensions citations

So far, Altmetric has seen 3 policy documents that reference this research output.

Genuttrycksprofil för beslut om adjuvant cytostatikabehandling vid hormonkänslig, HER2-negativ bröstcancer

Cited by Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) on 11 Jun 2019

SBU is an independent national authority, tasked by the government with assessing health care and social service interventions from a broad perspective, covering medical, economic, ethical and social aspects.

Genuttrycksprofil för beslut om adjuvant cytostatikabehandling vid hormonkänslig, HER2-negativ bröstcancer

Cited by Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) on 11 Jun 2019

Breast Cancer Management in the TAILORx Era: Less is More - National Academy of Medicine

Cited by National Academy of Medicine on 17 Dec 2018

The National Academy of Medicine (NAM), established in 1970 under the name Institute of Medicine (IOM), is an independent organization of eminent professionals from diverse fields including health and medicine; the natural, social, and behavioral sciences; and beyond.